Furthermore, the authors suggested that inhibitors that target IL-6, Fas, and STAT3 signaling pathways could abolish fascin-1 expression and could be used as an adjuvant treatment strategy for GC [74,75]. The gene discussed is STAT3; the disease is gastric cancer.